Isoray, Inc. announced that William Cavanagh III was terminated from his position of Chief Research and Development Officer of the Company on February 7, 2023.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.515 USD | +1.00% | -7.98% | +273.13% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+273.13% | 1.01B | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+42.10% | 40.47B | |
-10.02% | 27.17B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- CATX Stock
- News Perspective Therapeutics, Inc.
- Isoray, Inc. Announces Termination of William Cavanagh III as Chief Research and Development Officer